Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study

22Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Introduction: Cost-containment strategies are shifting the treatment of acute bacterial skin and skin structure infections (ABSSSI) from inpatient to outpatient settings. Current standard of care (SoC) requires multiple-dose regimens, which are associated with high hospitalization rates and high costs. Oritavancin, a new single-dose antibiotic for ABSSSI, may be suitable for outpatient therapy. This analysis evaluates the effectiveness, costs, and resource utilization of oritavancin vs. SoC in a real-world, outpatient setting. Methods: A single-site, retrospective chart review was conducted of 118 adult patients diagnosed with ABSSSI and treated with either single-dose oritavancin or multi-dose SoC therapy between 6 August 2014 and 30 June 2015. Patients were assigned to two matched cohorts: oritavancin and SoC. Primary clinical effectiveness endpoints was the success (cured or improved) at 5–30 days after the course of antibiotic therapy has been completed. Secondary economic endpoints were total costs and healthcare resource utilization. Results: Oritavancin showed comparable clinical effectiveness vs. multi-dose SoC in the outpatient setting. A similar percentage of patients in the oritavancin (90.2%) and SoC cohorts (77.4%) achieved successful outcomes (“cure” or “improved”), with the cure rate higher for oritavancin (73.2%) vs. SoC (48.4%; P = 0.0315). Oritavancin’s clinical effectiveness was consistent across patient subgroups with varying demographic, clinical, and ABSSSI characteristics. Oritavancin was consistently associated with lower costs (per-patient savings $2319) and reduced resource utilization measures, and it required just 1.0 day of therapy vs. 7.2 days for SoC. Conclusion: Oritavancin is well suited for the outpatient treatment of ABSSSI. Compared with SoC, oritavancin offers comparable effectiveness, is more economical, and requires fewer healthcare resources.

References Powered by Scopus

Methicillin-resistant S. aureus infections among patients in the emergency department

2093Citations
N/AReaders
Get full text

Community-associated methicillin-resistant Staphylococcus aureus: Epidemiology and clinical consequences of an emerging epidemic

1615Citations
N/AReaders
Get full text

Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America

1274Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK

79Citations
N/AReaders
Get full text

Outpatient parenteral antimicrobial therapy: Updated recommendations from the UK

32Citations
N/AReaders
Get full text

Real-World Use of Oritavancin for the Treatment of Osteomyelitis

21Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Anastasio, P. J., Wolthoff, P., Galli, A., & Fan, W. (2017). Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study. Infectious Diseases and Therapy, 6(1), 115–128. https://doi.org/10.1007/s40121-016-0145-7

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 7

54%

Researcher 3

23%

Professor / Associate Prof. 2

15%

Lecturer / Post doc 1

8%

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 7

41%

Medicine and Dentistry 7

41%

Economics, Econometrics and Finance 2

12%

Nursing and Health Professions 1

6%

Save time finding and organizing research with Mendeley

Sign up for free